Marielle Chiron

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle et al. · Clinical Cancer Research · 2014 · 321 citations

Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation

Lan Wu, Edward Seung, Ling Xu et al. · Nature Cancer · 2019 · 232 citations

Tumor Immunology, Tumor-directed T Cells, Cancer Immunosurveillance +8

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

Loredana Vecchione, Valentina Gambino, Jonne A. Raaijmakers et al. · Cell · 2016 · 85 citations · Full text

Potential Clinical Utility, Gastrointestinal Oncology, Medicine +6

Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer

Marielle Chiron, Rebecca G. Bagley, Jack Pollard et al. · Molecular Cancer Therapeutics · 2014 · 65 citations

Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker <i>Post Hoc</i> Analysis of the VELOUR Trial

Eric Van Cutsem, Caroline Paccard, Marielle Chiron et al. · Clinical Cancer Research · 2019 · 56 citations